Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction

Palatin Technologies, Inc. (NYSE MKT:

) lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD). The approval of flibanserin (under development by Sprout Pharmaceuticals) today by the U.S. Food and Drug Administration (FDA) marks a long-awaited milestone in healthcare for women.  The FDA's approval of flibanserin validates that there is an important need for women living with hypoactive sexual desire disorder, or HSDD, to have an approved treatment option. Palatin applauds the FDA's positive determination, which supports FDA's previous statements that HSDD is an unmet medical need requiring a safe treatment option for women with HSDD.  HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity, which causes a woman distress or puts a strain on the relationship with her partner, and cannot be accounted for by another medical, physical or psychiatric condition, or as a result of other medication. It is estimated that one in 10 women may have the signs of HSDD at some point in their life,